Guardant Health (GH) Financial Analysis & Valuation | Quarter Chart
Guardant Health (GH)
GHPrice: $153.74
Fair Value: 🔒
🔒score
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an... more
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics ... more
Description
Shares
| Market Cap | $20.39B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Helmy Eltoukhy |
| IPO Date | 2018-10-04 | CAGR | 0.5% |
| Employees | 1,999 | Website | guardanthealth.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
GH chart loading...
Fundamentals
Technicals
| Enterprise Value | $17.43B | P/E Ratio | -59.59 |
| Forward P/E | -392.34 | PEG Ratio | — |
| P/S Ratio | 29.29 | P/B Ratio | -172.96 |
| P/CF Ratio | -178.54 | P/FCF Ratio | -140.69 |
| EPS | $-2.58 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 39.56% | Gross Margin | 0.65% |
| Operating Margin | -0.41% | Profit Margin | -0.4% |
| ROE | 1.84% | ROA | -0.23% |
| ROCE | -0.28% | Current Ratio | 4.68 |
| Quick Ratio | 4.39 | Cash Ratio | 3.39 |
| Debt/Equity | -9.26 | Interest Coverage | -100.51 |
| Altman Z Score | 4.06 | Piotroski Score | 4 |